FibroGen, Inc. (FGEN)

Oncology Corporate Profile

Stock Performance

25.0500
1.9000

HQ Location

409 Illinois St.
San Francisco, CA 94158

Company Description

FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anemia, cancer, and other serious unmet medical needs. FibroGen’s FG-3019 fully human monoclonal antibody is in clinical development for treatment of idiopathic pulmonary fibrosis and other proliferative diseases, including pancreatic cancer and liver fibrosis. Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in clinical development for the treatment of anemia. FibroGen is also currently pursuing the use of proprietary recombinant human type III collagens in synthetic corneas for treatment of corneal blindness.

Website: http://www.fibrogen.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
FG-3109 (+ gemcitabine and erlotinib)anti-fibrotic antibodyPancreactic adenocarcinomaII

View additional information on product candidates here »

Source


http://www.fibrogen.com

Recent News Headlines

FIBROGEN INC Financials

3/7/2017 06:00 pm

FibroGen Reports Fiscal 2016 Financial Results

3/1/2017 09:00 pm

[GlobeNewswire] - SAN FRANCISCO, March 01, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and provided an update on the company’ ...

FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017

2/23/2017 03:03 am

[GlobeNewswire] - SAN FRANCISCO, Feb. 22, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, today announced that it will report financial results for the year ended December 31, 2016, on Wednesday, March ...

FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy

2/3/2017 04:00 pm

[GlobeNewswire] - SAN FRANCISCO, Feb. 03, 2017-- FibroGen, Inc.,, a science-based biopharmaceutical company, today announced that clinical results from the company’ s open-label, dose-escalation Phase 1/ 2 study of pamrevlumab ...

FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China

1/30/2017 12:00 pm

[GlobeNewswire] - SAN FRANCISCO, Jan. 30, 2017-- FibroGen, Inc., a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd., today reported positive topline results ...

Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium

1/20/2017 10:00 pm

[GlobeNewswire] - SAN FRANCISCO, Jan. 20, 2017-- FibroGen, Inc. today announced that updated results from an ongoing clinical study of pamrevlumab in combination with standard-of-care chemotherapy in patients with locally ...